Lyell Immunopharma Inc
Research Lyell Immunopharma Inc (LYEL) on Bullrun: market cap USD 362.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLYEL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 362.42M
- Financial periodQ2 2026
- RevenueUSD 4.00K
- Net income-USD 44.76M
- Free cash flow-USD 34.18M
Valuation Snapshot
latest market cap is USD 362.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 36.00K | -USD 274.45M | -USD 150.80M | n/a | -16.06 | USD 60.18M | USD 50.99M | USD 248.20M |
| FY2024 | USD 61.00K | -USD 342.99M | -USD 162.86M | n/a | -26.23 | USD 105.60M | USD 58.97M | USD 382.82M |
| FY2023 | USD 130.00K | -USD 234.63M | -USD 166.38M | n/a | -18.7 | USD 145.65M | USD 63.17M | USD 654.95M |
| FY2022 | USD 84.68M | -USD 183.12M | -USD 193.83M | n/a | -0.74 | USD 123.55M | USD 66.07M | USD 833.25M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 362.42M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 455.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 188.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 488.62M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 865.16M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.88B | n/a | n/a | n/a |
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Related stock research
Other Healthcare stocks
Adicet Bio Inc (1IJ)
Cartesian Therapeutics, Inc. (1S70)
QUOIN PHARMACEUT.ADR5000 (2EB0)
Aardvark Therapeutics Inc (AARD)
Abeona Therapeutics Inc (ABEO)
Acumen Pharmaceuticals Inc (ABOS)
Absci Corp (ABSI)
Arbutus Biopharma Corp (ABUS)
ABVC BioPharma Inc (ABVC)
Acadia Pharmaceuticals Inc (ACAD)
Adicet Bio Inc (ACET)
Achieve Life Sciences Inc (ACHV)
Frequently asked questions
What is Lyell Immunopharma Inc's market cap?
Lyell Immunopharma Inc's market capitalization is USD 362.42M.
What does Lyell Immunopharma Inc do?
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.